The GLP is committed to full transparency. Download and review our 2019 Annual Report

image oligomannate alzheimers drug china

China’s new Alzheimer drug greeted with ‘surprise and skepticism’ by researchers

China’s approval of the drug oligomannate earlier this month for treating mild to moderate Alzheimer’s disease has been met with surprise and ...
b ef a a d b c a

China’s new seaweed-based Alzheimer’s therapy raises hopes—and questions about safety, effectiveness

Chinese regulators have granted conditional approval to an Alzheimer’s drug that is derived from seaweed, potentially shaking up the field ...